FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2019/03/018167 [Registered on: 19/03/2019] Trial Registered Prospectively
Last Modified On: 16/05/2024
Post Graduate Thesis  No 
Type of Trial  Interventional 
Type of Study   Drug 
Study Design  Randomized, Parallel Group, Active Controlled Trial 
Public Title of Study   Phase IV study comparing Efonidipine 40mg Tablet to Cilnidipine 10 Mg Tablet In The Management Of Hypertension  
Scientific Title of Study   A Multicentric, Prospective, Comparative, Randomized Phase-IV Study For Evaluation Of Efficacy And Safety Of Efonidipine 40mg Tablet In Comparison to Cilnidipine 10 Mg Tablet In The Management Of Hypertension  
Trial Acronym   
Secondary IDs if Any  
Secondary ID  Identifier 
ZUV/EFFECT/HQ-04/2018   Protocol Number 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Bhupesh Dewan  
Designation  Director- Medical Services  
Affiliation  Zuventus Healthcare Limited  
Address  5119, D Wing, Oberoi Garden Estate, Chandivali, Andheri (E)

Mumbai
MAHARASHTRA
400 072
India 
Phone  022-30610000  
Fax    
Email  bhupesh.dewan@zuventus.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Bhupesh Dewan  
Designation  Director- Medical Services  
Affiliation  Zuventus Healthcare Limited  
Address  5119, D Wing, Oberoi Garden Estate, Chandivali, Andheri (E)

Mumbai
MAHARASHTRA
400 072
India 
Phone  022-30610000  
Fax    
Email  bhupesh.dewan@zuventus.com  
 
Details of Contact Person
Public Query
 
Name  Dr Bhupesh Dewan  
Designation  Director- Medical Services  
Affiliation  Zuventus Healthcare Limited  
Address  5119, D Wing, Oberoi Garden Estate, Chandivali, Andheri (E)

Mumbai
MAHARASHTRA
400 072
India 
Phone  022-30610000  
Fax    
Email  bhupesh.dewan@zuventus.com  
 
Source of Monetary or Material Support  
Zuventus Healthcare Limited, 5119, D Wing, Oberoi Garden Estate, Chandivali, Andheri (E), Mumbai- 400072  
 
Primary Sponsor  
Name  Zuventus Healthcare Limited  
Address  5119, D Wing, Oberoi Garden Estate, Chandivali, Andheri (E), Mumbai- 400072  
Type of Sponsor  Pharmaceutical industry-Indian 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study
Modification(s)  
No of Sites = 26  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Niranjan C Ambekar  Ambekar Hospital  Ground Floor, Plot No. 86, Opp. Jog School, Off Karve Road, Mayur Colony, Kothrud
Pune
MAHARASHTRA 
9822098670

dialysis97@gmail.com 
Dr Arun B Shah  Bharatiya Arogya Nidhi Hospital  1st floor, Dialysis unit, N.S. Road Number 13, Chand Society, Juhu,Vile Parle West
Mumbai
MAHARASHTRA 
9821133935

drarunshah56@gmail.com 
Dr C M Nagesh  Cardea clinic  "Jaiganesh", No 321, 1st floor, 36th A cross, 7th Main, 5th Block Jayanagar, Near Good Shepherd School
Bangalore
KARNATAKA 
9742263936

drnageshcm@yahoo.com 
Dr Vijay Alagappan  Dr. Vijay Alagappan Clinic  43/91, 7th Ave, Indira Colony, Ashok Nagar
Chennai
TAMIL NADU 
98844443526

vijrus@hotmail.com 
Dr Vijay Mandora   Dr. Vijay Mandoras Clinic  501-B Panna Chambers, Ghorpade Peth, Swargate
Pune
MAHARASHTRA 
9422037617

mandoravp@yahoo.co.in 
Dr N Krishna Reddy  Durgabai Deshmukh Hospital  1-9-27, Osmania University Rd, Vidya Nagar, Adikmet
Hyderabad
TELANGANA 
9849001616

nkreddy61@gmail.com 
Dr Krishna Kumar  Excel Hospital  Dept of Cardiology, 1-5-56/29, Old Alwal Road, Banda Basti, Alwal, Secunderabad, Telangana- 500010
Hyderabad
TELANGANA 
7731030321

doctorresearch1212@gmail.com 
Dr Gouranga Sarkar  Health Point Hospital   Room No. 12, 1st floor, Department of General Medicine, Health Point Hospital, 21, Prannath Pandit Street (Opp. Lansdown Padmapukur), Kolkata – 700025, West Bengal
Kolkata
WEST BENGAL 
9830165760

drgsmed@gmail.com 
Dr Chetan Shah  Heart Rhythm Clinic  3rd Floor, Manu Market, Mahatma Gandhi Road, Ghatkopar West
Mumbai
MAHARASHTRA 
9821115485

chetanshah@hotmail.com 
Dr Manoj Gupta  Indopath Clinical Pvt. Ltd.  1st floor, Indopath Clinical Pvt. Ltd., 87, Chowringhee Road, Near Rabindra Sadan, Metro Gate No. 4, Kolkata – 700020, West Bengal
Kolkata
WEST BENGAL 
9599038676

manojsrmc@gmail.com 
Dr Amit Bhaskar  Janta Hospital  Room no. 04, Clinical Research Department, 1st Floor, Janta Hospital, Near Water Head tank, Amara-Akhari by pass, Chunar Road, Varanasi- 221011, Uttar Pradesh
Varanasi
UTTAR PRADESH 
9580210470

dramitbhaskar@gmail.com 
Dr Arun K N  Kidney Care  Department of Nephrology, #10, Opp. Jain Hospital, Opposite Millers Tank Bund Road, Kaveri Appa Layout, Millers Road., Bangalore
Bangalore
KARNATAKA 
9844056001

drarunkn@yahoo.co.in 
Dr L Meenakshisundaram  L. M. Medical Centre  50/108, Goudiya Mutt Street, Royapettah
Chennai
TAMIL NADU 
9841219620

doctorlm26@yahoo.co.in 
Dr Umesh B Khanna  Lancelot Kidney & GI Centre  DIID2, Bharat Baug, Swami Vivekananda Rd, Shastri Nagar, Borivali West
Mumbai
MAHARASHTRA 
9821112487

ubkhanna@gmail.com 
Dr Sanjiv Saxena  Noble Medicare Clinic  C-2B/62A, Janakpuri
New Delhi
DELHI 
9810139839

drsanjivsaxena@rediffmail.com 
Dr K P Shamsuddeen  Olive Heart Clinic  18, 3rd Main Road, Seetammal Colony, MIG Colony, Alwarpet
Chennai
TAMIL NADU 
9840044287

kpshamsuddeen@gmail.com 
Dr Sanjeev Kumar A Hiremath  Ragavs Diagnostic & Research Centre Pvt.Ltd.  10/804-1, Patalamma Temple Road, Anebande Road, Jayanagar East
Bangalore
KARNATAKA 
9844137996

sanjeevhiremath@rediffmail.com 
Dr Mahesh Swamy  Ramya Hospital  Dept of Medicine, Room No.103, H: No. 2-96/1, Old Bowenpally Cross Road, Secunderabad, Telangana- 500011
Hyderabad
TELANGANA 
9666911868

doctorteam3@gmail.com 
Dr Chaitanya Reddy  Ray’s Diagnostics & Diabetes Centre  Plot No. 1-5-108/3/1, Near St. Michel School Road, Jannobanda, Old Alwal, Secunderabad, Telangana 500010
Hyderabad
TELANGANA 
9948027129

reddychaitanya543@gmail.com 
Dr Jayprakash Rathi  Remedy Hospital  Ground Floor, Medicine OPD, Ramanand Complex, Pune-Solapur Road, Near Janseva Bank & Hotel Krishna Chaya
Pune
MAHARASHTRA 
02026999186

remedyhospitalpune@gmail.com 
Dr Rajkumar Nikalje  Skinovate Laser & Cosmetic Clinic  Office No. 302 and 303, Third Floor, Royal Avenue, Survey No.I8, Hissa No.l1/6, Next to Hotel Shivar Garden, Pimple Saudagar, Rahatani, Taluka-Haveli
Pune
MAHARASHTRA 
9028560535

Nikaljeraj80@gmail.com 
Dr Srinivas Kulkarni   Sri Clinic  Shop No.3-4, 206/2, Kachiguda Station Rd, Lingampally, Kachiguda
Hyderabad
TELANGANA 
9849333914

srinivaskulkarni_dr@rediffmail.com 
Dr G Madanamohan  Sri Vaishnavi Diabeties Medical Centre  No.408, Poonamallee High Rd, Karthikeyan Nagar, Maduravoyal
Chennai
TAMIL NADU 
9444340651

no2snore@gmail.com 
Dr Lily Rodrigues  Surakshaka Multi-Speciality And Diabetes Hospitals  Room No.406, M.I.G 218, KPHB Colony Main Road, Landmark: Opposite KPHB Colony Metro Station KPHB
Hyderabad
TELANGANA 
9704799955

drrlily@gmail.com 
Dr Ashwani Mehta  The Heart Clinic  No. 13, Double Storey Market, New Rajinder Nagar
New Delhi
DELHI 
9811057384

drashwanimehta@gmail.com 
Dr Nikhil Reddy  TX Hospital  #2-6-71, Near Masjid, Bharat Nagar Colony, Uppal, Hyderabad, Telangana- 500039
Hyderabad
TELANGANA 
9849177789

nikhilnagireddy67@gmail.com 
 
Details of Ethics Committee
Modification(s)  
No of Ethics Committees= 26  
Name of Committee  Approval Status 
Excel Hospital Institutional Ethics Committee, Hyderabad  Approved 
ACE Independent Ethics Committee, Bangalore  Approved 
ACE Independent Ethics Committee, Bangalore  Approved 
ACE Independent Ethics Committee, Bangalore  Approved 
Excel Hospital Institutional Ethics Committee, Hyderabad  Approved 
Excel Hospital Institutional Ethics Committee, Telangana  Approved 
Excel Hospital Institutional Ethics Committee, Telangana  Approved 
Health Point Ethics Committee  Approved 
Health Point Ethics Committee  Approved 
Independent Ethics Committee Indian Fertility Society, New Delhi  Approved 
Independent Ethics Committee Indian Fertility Society, New Delhi  Approved 
Janta Hospital Ethics Committee  Approved 
Naitik Independent Ethics Committee, Pune  Approved 
Naitik Independent Ethics Committee, Pune  Approved 
Naitik Independent Ethics Committee, Pune  Approved 
Naitik Independent Ethics Committee, Pune  Approved 
RIPON Independent Ethics Committee, Chennai  Approved 
RIPON Independent Ethics Committee, Chennai  Approved 
RIPON Independent Ethics Committee, Chennai  Approved 
RIPON Independent Ethics Committee, Chennai  Approved 
Suraksha Ethics Committee, Thane  Approved 
Suraksha Ethics Committee, Thane  Approved 
Suraksha Ethics Committee, Thane  Approved 
Suraksha Institutional Ethics Committee, Hyderabad  Approved 
Suraksha Institutional Ethics Committee, Hyderabad  Approved 
Suraksha Institutional Ethics Committee, Hyderabad  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: I10||Essential (primary) hypertension, (2) ICD-10 Condition: I12||Hypertensive chronic kidney disease, (3) ICD-10 Condition: I15||Secondary hypertension,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Comparator Agent  Cilnidipine 10 mg tablet   One tablet of 10 mg to be taken orally once a day for 90 days 
Intervention  Efonidipine 40mg tablet   One tablet of 40 mg to be taken orally once a day for 90 days 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  65.00 Year(s)
Gender  Both 
Details  1. Patients aged 18 to 65 years
2. Patients with Stage 1 hypertension (SBP/DBP: 140-159/90-99 mmHg) or stage II(SBP/DBP: ≥160/100 mmHg) hypertension as per Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC VII)
2.1. Subgroup of patients with stage I hypertension: Patients diagnosed with Stage I hypertension (JNC VII)
2.2. Subgroup of patients with renal impairment: Stage I or stage II hypertensive patients (JNC VII) diagnosed with renal impairment who do not need dialysis or replacement therapy
2.3. Subgroup of patients with Diabetes: Stage I or stage II hypertensive (JNC VII) patients with diabetes
3. Patients willing to sign informed consent  
 
ExclusionCriteria 
Details  1. Patient with cerebrovascular disease in the previous 3 months.
2. Patients with congestive heart failure, chronic arrhythmia, sick sinus syndrome or sinus bradycardia (< 50 beats/min)
3. Patients with second- or third-degree atrioventricular block
4. Patients with documented hypersensitivity to dihydropyridine calcium channel blockers or Efonidipine HCl
5. Women who are pregnant or breast feeding  
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Pre-numbered or coded identical Containers 
Blinding/Masking   Participant and Investigator Blinded 
Primary Outcome  
Outcome  TimePoints 
1. Mean change in sitting Systolic Blood Pressure (SBP)
2. Mean change in sitting Diastolic Blood Pressure (DBP) 
From Baseline(Day 0) to Day 90 
 
Secondary Outcome  
Outcome  TimePoints 
1. Changes in proteinuria
2. Mean Change in Systolic Blood Pressure (SBP) From Baseline (Day 0) to Day 30 and 60
3. Mean Change in Diastolic Blood Pressure (DBP)
4. Number of subjects achieving target BP as per JNC VIII guidelines for Hypertension.
5. Number of subjects reporting incidences of adverse events or Serious Adverse events 
1. From baseline (Day 0) after Day 90
2. From Baseline (Day 0) to Day 30 and 60
3. From Baseline (Day 0) to Day 30 and 60
4. On day 90
5. Throughout study duration 
 
Target Sample Size   Total Sample Size="1200"
Sample Size from India="1200" 
Final Enrollment numbers achieved (Total)= "1200"
Final Enrollment numbers achieved (India)="1200" 
Phase of Trial   Phase 4 
Date of First Enrollment (India)   27/03/2019 
Date of Study Completion (India) 01/08/2023 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Date Missing 
Estimated Duration of Trial   Years="1"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)
Modification(s)  
Not Applicable 
Recruitment Status of Trial (India)  Completed 
Publication Details   Not yet published. 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Brief Summary   Study Title: A multicentric, prospective, comparative, randomized phase IV study for evaluation of efficacy and safety of efonidipine 40 mg tablet in comparison to cilnidipine 10 mg tablet in the management of hypertension.
Study Objective: To evaluate the efiicacy and safety of efonidipine 40 mg in comparison with clinidipine 10 mg tablets.
Primary Objective: To assess and compare the efficacy of efonidipine 40 mg and cilnidipine 10 mg in blood pressure reduction.
Secondary Objective: 
a) To evaluate and compare the effect of the two treatment groups on reduction of proteinuria.
b) To evaluate the number of patients achieving target BP as per JNC VIII guideline.
c) To evaluate and compare the safety of the two treatments over  a period of 3 months.
Estimated Sample Size: 1000 patients.A drop out rate of 20%shall be considered, therefore, total of 1200 patients may be recruited.
Treatment: Efonidipine and Cilnidipine groups will be randomised in 3:1 ratio.
Study endpoints:
Primary outcomes:
1. Mean change in sitting systolic blood pressure from day 0 to day 90.
2. Mean change in sitting diastolic blood  pressure from day 0 to day 90.
Secondary outcomes:
1. Changes in proteinuria from day 0 after day 90 of the treatment.
2. Mean change in systolic blood pressure from day 0 to day 30 and day 60.
3. Mean change in diastolic blood pressure from day o to day 30 and day 60.
4. Number of patients achieving target blood pressure as per JNC VIII guidelines for Hypertension.
5. Number of patients reporting incidences of adverse events or Serious adverse events

 
Close